Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank51
3Y CAGR-83.4%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-83.4%/yr
vs +96.8%/yr prior
Acceleration
-180.3pp
Decelerating
Percentile
P51
Within normal range
vs 3Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 0.61% |
| Q2 2025 | -31.68% |
| Q1 2025 | -10.20% |
| Q4 2024 | -3.50% |
| Q3 2024 | -34.32% |
| Q2 2024 | 70.78% |
| Q1 2024 | -773.55% |
| Q4 2023 | -0.03% |
| Q3 2023 | 47.55% |
| Q2 2023 | 18.68% |
| Q1 2023 | 0.71% |
| Q4 2022 | -316.24% |
| Q3 2022 | 134.62% |
| Q2 2022 | 43.28% |
| Q1 2022 | -16.09% |
| Q4 2021 | -9.11% |
| Q3 2021 | 38.05% |
| Q2 2021 | 13.09% |
| Q1 2021 | 58.02% |
| Q4 2020 | -448.66% |
| Q3 2020 | -12.37% |
| Q2 2020 | 62.39% |
| Q1 2020 | -5548.22% |
| Q4 2019 | 115.52% |
| Q3 2019 | 37.83% |
| Q2 2019 | 14.91% |
| Q1 2019 | -19.96% |
| Q4 2018 | 75.84% |
| Q3 2018 | -322.14% |
| Q2 2018 | -64.37% |
| Q1 2018 | 19.86% |
| Q4 2017 | -119.88% |
| Q3 2017 | 1335.00% |
| Q2 2017 | 6.54% |
| Q1 2017 | -12.64% |
| Q4 2016 | 71.73% |
| Q3 2016 | -70.96% |
| Q2 2016 | 29.43% |
| Q1 2016 | -34.49% |
| Q4 2015 | -87.59% |